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Abstract
Chronic obstructive pulmonary disease (COPD) still remains a serious problem for the public health care system,
since it commonly causes disability and mortality among the working population. Frequent combination of COPD
with concomitant diseases is a key factor in predicting COPD consequences. Recently, the number of patients
with a combination of COPD and overweight is on the increase, which is considered as a mutual aggravating
factor and negatively affects the prognosis of the disease in such patients.
The objective of this study was to investigate the diagnostic value of leptin in progression of COPD (III degree of
bronchial obstruction in patients with overweight) course by studying its level in blood serum.
Materials and methods: There were examined 112 patients with chronic obstructive pulmonary disease (COPD
GOLD III) in different phases of pathological process. The pulmonary function (PF) test was performed by means
of ”SPIROKOM” device (Ukraine). The degree of overweight was determined by calculating the body mass index
(BMI) using the formula I = m/h2 (m – body mass in kilograms, h – height, in square meters (kg/m2). The level of
leptin of systemic inflammatory markers was determined by a solid phase enzyme-linked immunosorbent assay
in blood serum: ”DRG Leptin Elisa” (Germany).
Results and conclusions: The study revealed that overweight leads to a more severe course of COPD (III
degree of bronchial obstruction), and the determination of leptin may serve as a diagnostic criterion in the
progression of this pathology.
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Problem statement and analysis of
the latest research
Chronic obstructive pulmonary disease (COPD) is
a common disease characterized by persistent pro-
gressive restriction of airway patency and remains
one of the most common human pathologies requir-
ing new global resources for its early diagnosis and
prevention of its rapid progression.
This disease is the focus of attention mainly be-
cause of its progressive course, loss of productivity,
high rates of disability and mortality [8]. Thuswise,
in 1990 COPD was ranked the 6th among all the
causes of death and in 2001 – 2.7 million people
died of this disease that accounted for 5% of all
lethal cases all over the world [16, 17, 25]. Accord-
ing to the data of the World Health Organization
(WHO), COPD affects 210 million people and its
incidence is expected to increase at 30% in ten years
(WHO, 2014). Furthermore, the key factor, which
determinates the urgency of COPD issue, is its high
treatment costs for both the health care system and
Diagnostic Value of Leptin in Chronic Obstructive Pulmonary Disease of the Iii Degree in
Patients with Excessive Body Weight — 2/7
society as a whole. The statistics of Global Initia-
tive (GOLD, 2019) shows that EU annual direct
COPD costs reach 38.6 billion euros. Total COPD
costs are three times higher than those for bronchial
asthma [7, 25].
Low level of early diagnosis of COPD, as well
as lack of awareness among the population and low
alertness of medical practitioners towards patients
with early symptoms and risk factors for the disease
development are the main causes of sharp increase
of COPD morbidity rates and mortality due to the
disease complications [5, 6, 14]. Recently, special
attention is paid to the fact that comorbid pathology
can exacerbate the course of COPD and is consid-
ered to be an important part of ”causative patho-
genetic cycle”. The likelihood of occurrence of sys-
temic reactions varies at different COPD stages, and
the frequency of their comorbid course increases
with the disease progression. Frequent combination
of COPD with comorbid conditions is a key factor
in predicting COPD consequences. Some of these
diseases develop irrespective of COPD, while oth-
ers have causative connection with COPD: these
diseases have either common risk factors, or one
disease increases the risk of development of other
pathology [25].
One of the conditions that can have a negative
impact on the course of COPD is the presence of
excess body weight, which can lead to the increased
morbidity and mortality, lost of productivity and dis-
ability, as well as a factor in the rapid progression of
a number of chronic diseases, including respiratory
tract pathology (L.M.Niu, 2012; N.Hizawa, 2013;
K.F. Rabe, 2014). According to the WHO normal
body mass index (BMI) is considered to be between
18.5 – 24.9 kg/m2, while the BMI of between 25.0 –
29.9 kg/m2 is considered as overweight.
The results of experimental and clinical scien-
tific studies intensively performed during the last
decade, revealed a new phenomenon: excessive
body weight is accompanied by inflammation of
adipose tissue, which occurs with its infiltration by
immune cells. Moreover, the severity of this inflam-
mation clearly correlates with the degree of obe-
sity [1, 2, 11, 13]. Since the inflammatory reaction
occurs in tissue that is well-vascularized and inner-
vated, the proportion of which can be up to 50% or
more of the total body weight, therefore systemic
manifestations should be expected [3, 4, 10]. Nowa-
days, it has been determined that adipose tissue pro-
duces many hormone-like substances, mediators,
cytokines and chemokines, which were generally
termed as adipokines or adipocytokines. They func-
tion both locally and systematically [9, 15]. Leptin
is one of the adipokines synthesized by the adipose
tissue; it activates inflammation, promotes angios-
teosis, initiates oxidative stress, increases the tone
of sympathetic nervous system, changes cytokine
regulation, which plays an important role in the
pathogenesis of inflammatory damage [1, 12, 22].
The key elements connecting COPD and over-
weight involve systemic inflammation and dysfunc-
tion of antioxidant mechanisms [10, 18, 19]. Signif-
icant vascularization of lungs, the presence of leptin
receptors in alveolar and bronchial epithelial cells,
smooth muscular cells and bronchial submucosal
membrane, as well as increased blood serum leptin
levels in patients with COPD exacerbation, allow
suggesting pathogenic contribution of leptin to the
disease progression [20, 21]. Leptin also activates
the production of mucin by the epithelial cells of
the airways, resulting in hypersecretion of mucus,
stimulates the synthesis of proinflammatory media-
tors that contribute to the increase of wall thickness,
subepithelial fibrosis, hypertrophy and proliferation
of bronchial smooth muscles [12, 21, 24].
At present, the implication of leptin is evidenced
both in COPD exacerbation and during its stable
period [21, 23, 24, 25, 26]. Many scientific studies
have been performed in order to research the role
of leptin in the development and course of COPD
in Ukraine and other countries. For example, there
are well-known publications which indicate that
adipokines are associated with systemic inflamma-
tion in COPD exacerbation [15, 20, 21, 25]. At
the same time, adipose tissue is considered to be
an additional source of inflammation [3, 7]. Thus-
wise, one of the studies show that the level of lep-
tin in adipose tissue correlated with the level of
inflammatory markers in systemic circulation [13,
15, 20]. However, during these studies (Krommi-
das G., 2010), patients were not classified accord-
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ing to the level of body overweight as compared
to the respiratory function, but were evaluated in
the general cohort. This issue was also studied in
patients with bronchial asthma, which proved the
increase of leptin level that is associated with the
decrease in pulmonary capacity (PC), forced vital
lung capacity (FVLC) and peak expiratory flow rate
(PEFR) [1, 10, 23]; however, the role of leptin in
the process of generalization of the inflammatory
response with FEV1 index below 50% in COPD
patients with excessive body weight still remains
uncertain.
The objective of the research work is to investi-
gate the diagnostic value of leptin in progression of
COPD GOLD III course in patients with excessive
body weight by studying its level in blood serum.
1. Materials and Methods
The verification of the diagnosis of COPD and its
formulation was carried out in accordance with In-
ternational Recommendation of the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD
2019), and the Order of the Ministry of Health of
Ukraine #555 dated June 27, 2013 ”On approval
and implementation of medical-technological docu-
ments on standardization of medical care in chronic
obstructive pulmonary disease”. Patients being in
a stable phase of the process received basic ther-
apy in accordance with the currently valid Order of
the Ministry of Health of Ukraine #555 dated June
27, 2013, which involved the use of long-acting
bronchodilators, inhalational and/or systemic glu-
cocorticosteroids, and, if necessary, short-acting
bronchodilators [14].
The main treatment group involved 45 patients
suffering from COPD GOLD (male patients – 37
(75.6%), female patients – 11 (24.4%) with obe-
sity); the average age was (61.9±3.1) years. They
were divided into subgroups depending on the phase
of the pathology: subgroup I included 18 patients
(40%) with stable phase of pathological process,
subgroup II involved 27 patients (60%) in the non-
infectious exacerbation phase. The experimental
group consisted of 67 COPD patients with the III
degree of bronchial obstruction (male patients – 51
(76.1%), female patients 17 (25.4%) with normal
body weight; average age – (62.9±2.8) years. They
were also divided into subgroups depending on the
phase of their pathology: subgroup I included 25
patients (37.3%) with stable phase of pathological
process, subgroup II involved 42 patients (62.7%)
in the non-infectious exacerbation phase.
The control group involved 23 apparently healthy
individuals (AHI) representative by sex and age,
without any signs of pulmonary diseases or other
pathologies of internal organs, 12 of them were
overweight. The study was performed in the phase
of remission and at the time of verification of the
development of exacerbation phase. All the studied
patients gave their consent to participate in clinical
trial.
The average duration of the disease in patients
with COPD of the III degree of bronchial obstruc-
tion was (26.8±1.4) years in those with overweight,
and (31.4±1.2) years in patients with normal body
weight. Among the existing risk factors, which trig-
gered the COPD development in both main treat-
ment group and comparison group, tobacco smok-
ing was prevalent: 29 individuals (64.4%) with av-
erage smoking history of (17.8±2.1) pack-years
and 48 individuals (71.6%) with average smoking
history of (19.9±2.2) pack-years, respectively.
Computed spirometry with the help of ”Spiro-
Com medic” (The National Aerospace University
”Kharkiv Aviation Institute”, Ukraine) was used to
study the indices of respiratory function with indi-
cators of main bronchial-obstructive indices (forced
vital capacity (FVC) of lungs, forced expiratory
volume (FEV1)), according to the criteria GOLD
2014.
The levels of leptin in blood serum was de-
termined using a solid phase enzyme-linked im-
munosorbent assay with agent ”DRG Leptin ELISA”
(Germany).
Statistical processing of research materials was
carried out using biometric analysing methods im-
plemented in software packages Microsoft Office
Excel 2016 (Microsoft Corp., the USA). The assess-
ment of statistical significance of mean values for
independent samples was performed according to
the Student’s and Mann-Whitney tests, while dis-
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Table 1. Table 1. Indices of respiratory function (%) in COPD patients with the III degree of bronchial
obstruction in relation to the body weight, (M±m).
Indices in subgroups of examined patients Rated values
Phase of remission Exacerbation phase
FEV1 (%)
Main treatment group, (n=45) 40.2±3.1 33.3±3.0
Comparison group, (n=67) 45.5±3.4 38.4±3.2
FVC (%)
Main treatment group, (n=45) 67.3±3.0 62.6±3.6
Comparison group, (n=67) 72.6±3.7 69.1±3.1
FEV1/ FVC
Main treatment group, (n=45) 55.2±3.2 53.4±3.1
Comparison group, (n=67) 57.5±3.8 57.1±3.0
persion was evaluated with the help of Fisher’s test.
The difference between the comparative values was
considered to be significant at p<0.05, while the
tendency of changes was indicated in the range of
0.05<p<0.10, with the index rate calculated to the
decimal place.
2. Results and Discussion
The values of main spirometric indices of respira-
tory function in the main treatment group and the
comparison group were identical (Table1).
Laboratory findings show that serum leptin level
in patients with COPD GOLD III with normal body
weight in the remission phase was 1.6-fold (p>0.05)
higher as compared to the control group, and in-
creased significantly with the destabilization of the
process. Thus, in the exacerbation phase, the blood
serum leptin level was 1.4-fold (p>0.05) higher
than in the remission phase and 2.2-fold (p<0.05)
higher than the control group data (Table 2).
The highest blood serum leptin level was ob-
served in patients suffering from COPD GOLD III
with overweight. This index in the remission phase
was 2.4-fold higher (p<0.05) than the control group
indices. In the phase of pathology exacerbation the
blood serum leptin level in patients with COPD
GOLD III with excessive body weight was 1.8-fold
(p<0.05) higher than the indices in the remission
phase, and 4.4-fold (p<0.05) higher than the indices
observed in control group.
The study showed correlation between the level
of leptin and excessive body weight that is evi-
denced by the increase of indices obtained in main
group of patients. Namely, serum levels of leptin
in patients with COPD GOLD III with excessive
body weight in the remission phase were 2.6-fold
(p<0.05), and in the exacerbation phase – 3.3-fold
(p<0.05) higher than the corresponding indices in
patients with COPD GOLD III with normal body
weight.
We have studied ESR in order to bring accessi-
bility to general practitioners – in family medicine
and reduce financial burden in parallel with leptin
level.
The study also showed deviations in laboratory
indices of patients with COPD GOLD III. Thus,
the ESR index in such patients has increased up to
(12.9±2.1) mm/h, and in patients with overweight
this index was (17.8±2.3) mm/h, but more pro-
nounced changes were observed in patients with
destabilization of the process. Accordingly, the in-
dex of ESR in patients with normal body weight
increased up to (17.3±2.5) mm/h, and in patients
with excessive body weight it was (22.5±2.0) mm/h.
Moreover, we have established a correlation be-
tween the increase in leptin level with the increase
of ESR (r=0.92; p<0.05); p<0.05) index during
destabilization of the disease course and develop-
ment of the exacerbation phase of chronic obstruc-
tive pulmonary disease (III degree of severity) in
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Table 2. The level of leptin and ESR in studied patients with COPD of the III degree of bronchial
obstruction depending on the body weight, (M±m).
Main Group Comparison Group
Indices 1 subgroup 2 subgroup
Control
group,
1 subgroup 2 subgroup
Control
group,
Remission
phase, n=18
Exacerbation
phase, n=27
n-12
Remission
phase, n=25
Exacerbation
phase, n=42
n=11
Leptin, ng/ml 29.5±4.1*◦ 53.1±4.7#◦ 12.0±2.4 11.5±2.2* 16.1±2.7# 7.2±1.3
ESR, mm/h 17.8±2.7*◦ 22.5±2.0#◦ 11.7± 3.1 12.9±3.0* 17.3±2.5# 9.7±3.2
Notes:
* – statistically significant difference of the index compared to the control group (p<0.05);
# – statistically significant difference of the index in the comparison between the phase of remission and the phase
of exacerbation of the pathologic process (p<0.05);
◦ – statistically significant difference compared with the corresponding index in the comparison groupof patients
(p<0.05).
patients with excessive body weight.
Analyzing the obtained data it should be as-
sumed that the pathogenetic role of leptin in the
course and rapid progression of COPD GOLD III
in patients with excessive body weight belongs to
its proinflammatory effect.
3. Conclusions
1. Overweight is a factor in rapid progression
of COPD GOLD III, that is evidenced by 1.2-
fold shorter duration of the disease (p<0.05)
with parallel decrease at 2.1 pack-years of
smoking history.
2. COPD (III degree of bronchial obstruction)
in the remission phase in patients with exces-
sive body weight is accompanied by more
significant increase in the blood serum leptin
level 2.6-fold (p<0.05) and ESR – 1.4-fold
(p<0.05), as compared with the correspond-
ing indices in patients with normal body weight.
3. The development of exacerbation phase of
COPD GOLD III in patients with excessive
body weight is accompanied by even more
dramatic increase in the level of leptin at
69.7% as compared with the indices observed
in patients with normal body weight, and
moreover, these changes correlate with the
increase of ESR level (r=0.92; p<0.05).
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